Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials

Chen, Jun-Yuan; Li, Jieruo; Li, Ruobin; Wang, Huajun; Yang, Jie; Xu, Jichun; Zha, Zhengang

doi:10.1093/pm/pnw262

Cited by 39 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the FDA lifted its hold in March 2015, and in 2017 granted fast-track status as a nonopioid pain medication, 180 particularly for hip and knee osteoarthritis. 181 In the only reported study in DPN, 20 mg of SC tanezumab was administered on day 1 and week 8 and showed a reduction in DPN pain but no improvement in patients' global assessment of pain. 182 Vitamin D deficiency is associated with paresthesia and parasympathetic dysfunction 183,184 and is highly prevalent in diabetic populations.…”

Section: Intravenous Lidocainementioning

confidence: 96%

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Iqbal

Azmi

Yadav

et al. 2018

Clinical Therapeutics

374

249

View full text Add to dashboard Cite

show abstract

Section: Intravenous Lidocainementioning

confidence: 96%

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Iqbal

Azmi

Yadav

et al. 2018

Clinical Therapeutics

374

249

View full text Add to dashboard Cite

show abstract

“…In the past two years, several systematic reviews (13–15) have concluded that, compared to placebo, blockade of NGF with targeted monoclonal antibodies yielded substantial improvement in pain and in function. Tanezumab, used at doses of 5 mg and 10 mg, was statistically significantly superior to the active comparators, NSAIDs or opiates, with standardized effect sizes of 0.22 to 0.24 (13, 16).…”

mentioning

confidence: 99%

“…Tanezumab, used at doses of 5 mg and 10 mg, was statistically significantly superior to the active comparators, NSAIDs or opiates, with standardized effect sizes of 0.22 to 0.24 (13, 16). Chen et al reported that low dose (≤2.5mg) tanuzemab treatment had comparable efficacy to high dose, but with significantly fewer adverse effects (15). Since then, development of higher dose anti-NGF has ceased.…”

mentioning

confidence: 99%

Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

Miller

Block

Malfait

2017

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Anti-NGF antibodies hold tremendous potential for the management of osteoarthritis (OA) pain, but clinical trials have revealed serious adverse effects that are incompletely understood. This review discusses clinical trial results along with preclinical studies that have assessed NGF blockade in experimental OA, in order to provide insight for future studies. Recent findings Systematic reviews have revealed that anti-NGF therapy, including tanezumab, is efficacious in improving pain and function, but serious adverse events, including rapidly progressive OA and osteonecrosis, resulted in a moratorium on trials that was only recently lifted. Within the past year, preclinical testing has revealed effects of NGF blockade on both pain behaviors and joint structure in experimental models of OA. Similar to clinical trial results, these studies in laboratory animals demonstrated analgesic efficacy of NGF blockade. Interestingly, several animal studies have suggested detrimental effects on joint integrity as a result of treatment, particularly when treatment is started early in the disease, when joint damage is mild to moderate. Summary NGF blockade continues to represent a promising new approach for the treatment of OA pain, but the actual benefits and risks remain to be fully elucidated. Preclinical models may suggest patient populations that could be best served while limiting side effects, but future work should further investigate the mechanisms of benefits and unwanted side effects.

show abstract

“…102 Currently, no DMOADs have been licensed for use in the treatment of OA, but several putative DMOADs are in phase II development. In particular, monoclonal antibodies (mAbs) and inhibitors directed against OA-related cytokines, such as tumor necrosis factor α (TNF-α), [103][104][105][106] nerve growth factor, [107][108][109] or interleukin molecules like IL-1α/β, [110][111][112] are under investigation, due to their regular use as biological disease-modifying antirheumatic drugs (bDMARDs) for the management of rheumatoid arthritis inflammation. 113 In a report comparing safety outcomes of bDMARDs in rheumatoid arthritis in 42 observational studies, a general safety profile of bDMARDs emerged with very sporadic cases of cardiovascular and infection incidence.…”

Section: Monoclonalmentioning

confidence: 99%

Management of Osteoarthritis During the COVID‐19 Pandemic

Ragni

Mangiavini

Viganò

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The pandemic spread of the new coronavirus disease 2019 (COVID‐19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID‐19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID‐19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age‐related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID‐19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID‐19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID‐19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision‐making tool to treat their OA patients as the coronavirus pandemic continues.

show abstract

Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials

Cited by 39 publications

References 29 publications

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy

Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

Management of Osteoarthritis During the COVID‐19 Pandemic

Contact Info

Product

Resources

About